Key Points
- Director Luke Evnin sold 67,950 shares of Werewolf Therapeutics on May 26 at an average price of $0.47, totaling about $31,936.50. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and his direct ownership fell by 8.17%.
- This was part of a series of insider sales by Evnin in recent weeks, including multiple transactions in May at prices ranging from about $0.42 to $0.70 per share. In total, the article highlights a notable pattern of repeated selling activity.
- Werewolf Therapeutics remains a small, struggling biotech with a market cap of about $22.5 million and shares near their 12-month low of $0.40. The company recently beat quarterly EPS estimates, but analysts still have a consensus Hold rating with a $3.75 average price target.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 36,387 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $0.42, for a total transaction of $15,282.54. Following the transaction, the director directly owned 919,060 shares of the company's stock, valued at $386,005.20. This represents a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
- On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
- On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
- On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.
- On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total transaction of $11,092.00.
- On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
- On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
- On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70.
- On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $49,824.18.
- On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total transaction of $9,659.10.
Werewolf Therapeutics Trading Up 4.4%
Shares of Werewolf Therapeutics stock opened at $0.46 on Wednesday. Werewolf Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $2.38. The stock has a market cap of $22.51 million, a PE ratio of -0.37 and a beta of 0.41. The company has a 50-day moving average of $0.77 and a two-hundred day moving average of $0.76.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04. On average, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the stock. Wall Street Zen cut shares of Werewolf Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $3.75.
Read Our Latest Analysis on HOWL
Institutional Trading of Werewolf Therapeutics
Several large investors have recently modified their holdings of the business. Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock valued at $429,000 after purchasing an additional 221,766 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the third quarter valued at approximately $304,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
